证券代码：002074 证券简称：国轩高科 公告编号：2025-055 期权的第三个行权期符合行权条件的激励对象合计 1,406 名，涉及可行权的股票 期权数量为 942.048 万份（实际行权数量以中国证券登记结算有限责任公司深圳 分公司登记为准），占公司目前总股本的 0.522%，行权价格为 18.47 元/份。 相应的行权手续后方可行权，届时公司将发布提示性公告，敬请投资者注意。 国轩高科股份有限公司（以下简称"公司"） 于2025年8月28日召开第九届董 事会第十三次会议及第九届监事会第十三次会议，审议通过了《关于2022年股票 期权激励计划首次授予第三个行权期行权条件成就的议案》，该事项已经公司 计划》的相关规定，董事会认为公司2022年股票期权激励计划首次授予的股票期 权第三个行权期行权条件已经成就，现将相关事项公告如下： 一、本激励计划已履行的审批程序和披露情况 通过了《关于 <公司 ensp="ensp" 年股票期权激励计划="年股票期权激励计划" 草案="草案"> 及其摘要 的议案》《关 于 <公司 ensp="ensp" 年股票期权激励计划实施考核管理办法="年股票期权激励计划实施考核管理 ...

行权价格由 39.10 元/股调整为 39.00 元/股。现将具体情况说明如下： 一、本激励计划已履行的相关审批程序 关于调整 2021 年股票期权激励计划行权价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 国轩高科股份有限公司（以下简称"公司"）于 2025 年 8 月 28 日召开了第九 届董事会第十三次会议及第九届监事会第十三次会议，审议通过了《关于调整 案已实施完毕，根据《公司 2021 年股票期权激励计划》 （以下简称"本激励计划"） 和 2021 年第三次临时股东大会的授权，董事会同意公司将本激励计划股票期权 证券代码：002074 证券简称：国轩高科 公告编号：2025-051 国轩高科股份有限公司 通过了《关于 <公司 ensp="ensp" 年股票期权激励计划="年股票期权激励计划" 草案="草案"> 及其摘要 的议案》《关 于 <公司 ensp="ensp" 年股票期权激励计划实施考核管理办法="年股票期权激励计划实施考核管理办 法"> 的议案》《关于提请股东 大会授权董事会办理 2021 年股票期权激励计划有关事项的议案》，关 ...

近日，公司已向中国证券登记结算有限责任公司深圳分公司提交注销上述股 票期权的申请。截至本公告披露日，经中国证券登记结算有限责任公司深圳分公 司审核确认，公司已完成上述合计 46,332,882 份股票期权的注销事宜。 山东未名生物医药股份有限公司 关于 2023 年股票期权激励计划部分股票期权 注销完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 山东未名生物医药股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召开了第五届董事会第三十六次会议、第五届监事会第二十三次会议、第五届 董事会薪酬与考核委员会第九次会议，审议通过了《关于 2023 年股票期权激励 计划第二个行权期行权条件未成就及注销部分股票期权的议案》，因公司层面业 绩考核目标未成就及部分激励对象离职，公司本次拟对 2023 年股票期权激励计 划第二个行权期及对应离职注销人员合计 29,715,486 份股票期权进行注销。具 体内容详见公司于 2025 年 4 月 29 日在巨潮资讯网（www.cninfo.com.cn）披露 的《关于 2023 年股票期权激励计划第二个行 ...

Core Viewpoint - The company has adjusted the exercise price of the stock options in its 2024 incentive plan from 106.00 CNY per share to 102.15 CNY per share due to the completion of a cash dividend distribution [1][4][5]. Summary by Sections 1. Adjustment of Stock Option Exercise Price - The exercise price for both the initial and reserved stock options has been adjusted to 102.15 CNY per share from the previous 106.00 CNY per share [1][3][5]. 2. Approval Process - The adjustment was approved during the sixth board meeting held on August 29, 2025, following the necessary decision-making procedures [1][4]. - Legal opinions and independent financial advisory reports were provided to support the adjustment [1][3][6]. 3. Reason for Adjustment - The adjustment was necessitated by the company's cash dividend distribution of 3.85 CNY per share, totaling approximately 587.42 million CNY, which was implemented on May 27, 2025 [4][5]. 4. Impact of Adjustment - The adjustment complies with relevant regulations and will not have a significant impact on the company's financial status or operational results [5][6]. 5. Opinions from Committees - The Board's Compensation and Assessment Committee has expressed that the adjustment does not harm the interests of the company or its shareholders [5][6].

上海君澜律师事务所 关于 浙江春风动力股份有限公司 调整 2024 年股票期权激励计划行权价格及 向激励对象预留授予股票期权相关事项 二〇二五年八月 上海君澜律师事务所 法律意见书 上海君澜律师事务所 关于浙江春风动力股份有限公司 调整 2024 年股票期权激励计划行权价格及 向激励对象预留授予股票期权相关事项之 法律意见书 致：浙江春风动力股份有限公司 上海君澜律师事务所（以下简称"本所"）接受浙江春风动力股份有限公 司（以下简称"公司"或"春风动力"）的委托，根据《上市公司股权激励管 理办法》（以下简称"《管理办法》"）及《浙江春风动力股份有限公司 2024 年股票期权激励计划》（以下简称"《激励计划》"或"本次激励计划"）的 规定，就春风动力调整本次激励计划行权价格及向激励对象预留授予股票期权 相关事项（以下简称"本次调整及授予"）出具本法律意见书。 对本法律意见书，本所律师声明如下： （一）本所律师依据《中华人民共和国证券法》《律师事务所从事证券法 律业务管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定及 本法律意见书出具日以前已经发生或者存在的事实，严格履行了法定职责，遵 循了勤勉尽责和 ...

Core Viewpoint - The announcement details the stock option incentive plan for 2024 by Zhejiang Chunfeng Power Co., Ltd, including the allocation of stock options to 306 eligible individuals at an exercise price of 102.15 yuan per share, with a total of 248,100 stock options reserved for this purpose [1][3][12]. Group 1: Stock Option Plan Details - The stock option reserve authorization date is set for August 29, 2025 [1]. - The exercise price for the reserved stock options is adjusted from 106.00 yuan to 102.15 yuan per share [3][12]. - A total of 327,000 stock options were granted to 1,291 individuals in the initial grant [3]. Group 2: Approval Process - The stock option incentive plan has undergone necessary decision-making procedures, including approval from the board and the remuneration and assessment committee [1][5]. - Legal opinions and independent financial advisory reports were provided to ensure compliance with regulations [5][16]. Group 3: Eligibility and Conditions - The plan specifies that stock options can only be granted if certain conditions are met, including the absence of negative audit opinions and compliance with legal regulations [5][8]. - The eligibility criteria for the incentive recipients include core management and technical personnel, excluding independent directors and major shareholders [12][13]. Group 4: Performance Targets - The performance targets for the stock options include cumulative revenue of at least 30.5 billion yuan for 2024 and 2025, and 50.5 billion yuan for 2024 to 2026 [9]. - Individual performance assessments will determine the ability of recipients to exercise their options based on their performance evaluations [9][10]. Group 5: Financial Impact - The total estimated expense for the stock options granted is approximately 41.53 million yuan, which will be amortized over the relevant periods [14][15]. - The financial impact will be recorded in accordance with accounting standards, reflecting the number of options that become exercisable [13][15].

证券代码：603681 证券简称：永冠新材 公告编号：2025-072 转债代码：113653 转债简称：永22转债 上海永冠众诚新材料科技（集团）股份有限公司 监事会关于 2025 年股票期权激励计划 首次授予激励对象名单的核查意见及公示情况说明 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海永冠众诚新材料科技（集团）股份有限公司（以下简称"公司"）于 2025 年 8 月 19 日召开第四届董事会第二十次会议、第四届监事会第十二次会议，审 议通过了《关于 <上海永冠众诚新材料科技 ensp="ensp" 年股票期="年股票期" 股份有限公司="股份有限 公司" 集团="集团"> 权激励计划（草案）>及其摘要的议案》等相关议案，根据《上市公司股权激励 管理办法》（以下简称"《管理办法》"）和《公司 2025 年股票期权激励计划（草 案）》（以下简称"《激励计划》"或"本激励计划"）的规定，公司对激励对象的 姓名和职务进行了内部公示，监事会结合公示情况对本激励计划首次授予激励对 象名单进行了核查，具体情况如下： 一、公司 ...

Core Viewpoint - The company held its 19th meeting of the 12th Supervisory Board on August 28, 2025, where several key resolutions were passed regarding the company's financial reports, fundraising management, stock option plan, and structural changes to the supervisory framework [1][2][3][4]. Group 1: Financial Reports - The Supervisory Board approved the company's 2025 semi-annual report and summary, confirming that the report's preparation and review processes complied with legal and regulatory requirements, accurately reflecting the company's operational and financial status [1]. - The board also approved a special report on the storage and actual use of raised funds, affirming that the company disclosed this information timely and accurately, with no violations in fund management [2]. Group 2: Stock Option Plan - The board approved the cancellation of unexercised stock options from the 2019 stock option incentive plan, stating that this action complies with relevant laws and regulations, and does not harm the interests of the company or its shareholders [2]. Group 3: Structural Changes - The board approved the proposal to abolish the Supervisory Board and amend the company's articles of association, transferring the supervisory functions to the Audit Committee of the Board, in line with updated legal and regulatory requirements [3][4]. - The board also approved the proposal to abolish the "Supervisory Meeting Rules," which will be submitted for shareholder approval [4].

Core Viewpoint - Beijing Electronic City High-Tech Group Co., Ltd. plans to cancel a total of 188,667 stock options from its 2019 stock option incentive plan that have not been exercised by 13 incentive targets as the third exercise period has expired [1][7]. Group 1: Stock Option Incentive Plan Overview - The stock option incentive plan was approved and implemented following necessary procedures, including independent opinions from the board [2][3]. - The plan received approval from the State-owned Assets Supervision and Administration Commission on June 12, 2019 [2]. Group 2: Reasons and Details for Cancellation - The cancellation is based on the stipulation that unexercised stock options must be terminated after the exercise period ends, as per the incentive plan [7]. - The total number of stock options to be canceled is 188,667, which were part of the reserved grant for the third exercise period [7]. Group 3: Impact and Compliance - The cancellation of stock options will not have a significant impact on the company's financial status or operational results [7]. - The supervisory board confirmed that the cancellation process complies with relevant laws and regulations, ensuring no harm to the interests of the company or its shareholders [7][8]. Group 4: Future Actions - The company will proceed with the necessary procedures for the cancellation of the stock options in accordance with the regulations of the Shanghai Stock Exchange and the China Securities Depository and Clearing Corporation [8].

Core Viewpoint - The board of directors of Guangxi Liuyuan Pharmaceutical Group Co., Ltd. held its 28th meeting, approving several key proposals including the half-year report and various governance changes aimed at enhancing operational efficiency and corporate governance [1][2][3]. Meeting Details - The board meeting was held on August 28, 2025, with all 7 directors present, ensuring compliance with legal and procedural requirements [1]. Financial Reports - The board approved the 2025 half-year report and its summary, with unanimous support from all directors [2]. - A special report on the use of raised funds was also approved, reflecting accurate management of funds during the reporting period [2]. Governance Changes - The board approved a proposal to change the registered capital and abolish the supervisory board, transferring some supervisory functions to the audit committee [3][4]. - A comprehensive revision of the company's articles of association was proposed to align with governance and regulatory requirements [3][4]. Risk Management - The board proposed purchasing liability insurance for directors and senior management to mitigate operational risks, with the proposal to be submitted to the shareholders' meeting due to conflicts of interest [7]. Incentive Plans - The board approved a draft for the 2025 stock option incentive plan aimed at attracting and retaining talent, which will also be submitted for shareholder approval [10][11]. - A management method for the stock option incentive plan was also approved, ensuring alignment with corporate goals [11][12]. Employee Stock Ownership Plan - The board approved a draft for the 2025 employee stock ownership plan to enhance employee engagement and align interests with shareholders, pending shareholder approval [15][16]. - A management method for the employee stock ownership plan was also established, ensuring compliance with relevant regulations [16][17]. Upcoming Meetings - The board scheduled the second extraordinary shareholders' meeting for September 15, 2025, to review the approved proposals [18].